bioRxiv Science⌕ Search

Biology subjects

Muranen, T. A.

Publications and source records attributed to Muranen, T. A..

2 recordsLinked to original sources

SegmentQTL: Identifying genetic variants influencing molecular phenotypes in copy number-driven cancers

MotivationMolecular quantitative trait loci (molQTL) analysis links genetic variants to molecular phenotypes, such as gene expression, but existing tools do not account for the structural complexity of copy number-driven cancers. High genomic instability of these cancers leads to chromosomal breaks (breakpoints), which disrupt the physical connection between genes and adjacent regulatory elements. Standard molQTL methods are unable to accommodate breakpoint information and would therefore indiscriminately test associations across breakpoints, leading to spurious signals and reduced biological relevance. To address these challenges, we developed SegmentQTL, a segmentation-aware molQTL analysis tool, designed to improve the accuracy of association testing in unstable cancer genomes by incorporating sample-specific break-point information. ResultsSegmentQTL applies an integrated purifying filtering step that removes associations spanning breakpoints, ensuring that only variants within the same segment as the phenotype are tested. This prevents false discoveries and reduces background noise. We evaluated SegmentQTL on selected genes from stable and unstable genomic regions and compared its results with a previously published state-of-the-art tool. In stable regions, SegmentQTL produced similar results, validating its approach. In unstable regions, however, the filtering step refined detected associations by shifting peak locations and removing artefactual signals that would arise if genomic instability were not properly accounted for. Availability and implementationhttps://github.com/HautaniemiLab/SegmentQTL

bioinformatics↗

Multi-Omics Analysis Reveals the Attenuation of the Interferon Pathway as a Driver of Chemo-Refractory Ovarian Cancer

Ovarian high-grade serous carcinoma (HGSC) represents the deadliest gynecological malignancy, with 10-15% of patients exhibiting primary resistance to first-line chemotherapy. These primarily chemo-refractory patients have particularly poor survival outcomes, emphasizing the urgent need for developing predictive biomarkers and novel therapeutic approaches. Here, we show that interferon type I (IFN-I) pathway activity in cancer cells is a crucial determinant of chemotherapy response in HGSC. Through a comprehensive multi-omics analysis within the DECIDER observational trial (ClinicalTrials.gov identifier NCT04846933) cohort, we identified that chemo-refractory HGSC is characterized by diminished IFN-I and enhanced hypoxia pathway activities. Importantly, IFN-I pathway activity was independently prognostic for patient survival, highlighting its potential as a biomarker. Our results elucidate the heterogeneity of treatment response at the molecular level and suggest that augmentation of IFN-I response could enhance chemosensitivity in refractory cases. This study underscores the potential of the IFN-I pathway as a therapeutic target and advocates for the initiation of clinical trials testing external modulators of the IFN-I response, promising a significant stride forward in the treatment of refractory HGSC.

cancer biology↗